Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis.

Int J Mol Sci · 2023 · PMC9866163 · PMID 36674537

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

ASAS40 response, universally considered a highly significant secondary endpoint, was greater with tofacitinib than with placebo (40.6% vs. 12.5%).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.